Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, AXIM Biotechnologies's Enterprise Value is $8.43 Mil.
AXIM Biotechnologies's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 was $-0.67 Mil. Therefore, AXIM Biotechnologies's EV-to-OCF for today is -12.50.
The historical rank and industry rank for AXIM Biotechnologies's EV-to-OCF or its related term are showing as below:
AXIM'
s EV-to-OCF Range Over the Past 10 Years
Min: -384.9 Med: -6.09 Max: -0.97
Current: -12.5
During the past 13 years, the highest EV-to-OCF of AXIM Biotechnologies was -0.97. The lowest was -384.90. And the median was -6.09.
AXIM's EV-to-OCF is not ranked
in the Biotechnology industry.
Industry Median: -3.45
vs AXIM: -12.50
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AXIM Biotechnologies's PE Ratio (TTM) for today is calculated as:
AXIM Biotechnologies's share price for today is $0.0026.
AXIM Biotechnologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
AXIM Biotechnologies EV-to-OCF Related Terms
AXIM Biotechnologies EV-to-OCF Historical Data
* Premium members only.
The historical data trend for AXIM Biotechnologies's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AXIM Biotechnologies's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AXIM Biotechnologies EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where AXIM Biotechnologies's EV-to-OCF falls into.
AXIM Biotechnologies's current Enterprise Value is $8.43 Mil.
AXIM Biotechnologies's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AXIM Biotechnologies (AXIM) has a EV-to-OCF of -12.50 as of Aug. 10, 2026.
Is AXIM Biotechnologies' EV-to-OCF too high?
AXIM Biotechnologies' current EV-to-OCF is -12.50.
How does AXIM Biotechnologies' EV-to-OCF compare to ZVSA and HEPA?
AXIM Biotechnologies' EV-to-OCF of -12.50 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. AXIM Biotechnologies's current EV-to-OCF is -12.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current EV-to-OCF of -12.50. The current EV-to-OCF is -12.50. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current EV-to-OCF is -12.50 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AXIM has been successfully added to your 
